According to Astellas Pharma's latest financial reports the company's current EPS (TTM) is โน26.89. a decrease over its 2023 EPS that were of โน35.25.
Year | EPS | Change |
---|---|---|
2024 | โน5.44 | -84.56% |
2023 | โน35.25 | -26.17% |
2022 | โน47.74 | -6.03% |
2021 | โน50.80 | -39.48% |
2020 | โน83.94 | -6.54% |
2019 | โน89.81 | 35.86% |
2018 | โน66.11 | -18.13% |
2017 | โน80.75 | 16.79% |
2016 | โน69.14 | 55.72% |
2015 | โน44.40 | 30.75% |
2014 | โน33.96 | 14.69% |
2013 | โน29.61 | 234.36% |
2012 | โน8.86 | -70.92% |
2011 | โน30.45 | -37.01% |
2010 | โน48.35 | -22.7% |
2009 | โน62.55 | 5.52% |
2008 | โน59.28 | 73.03% |
2007 | โน34.26 | 28.94% |
2006 | โน26.57 | 77.19% |
2005 | โน14.99 | -24.21% |
2004 | โน19.78 |